Abstract
Objective
To evaluate the efficacy and safety of Chinese medicine (CM) plus Western medicine (WM) in the treatment of pediatric patients with severe hand, foot and mouth disease (HFMD) by conducting a prospective, controlled, and randomized trial.
Methods
A total of 451 pediatric patients with severe HFMD were randomly assigned to receive WM therapy alone (224 cases, WM therapy group) or CM [Reduning Injection (热 毒宁注射液) or Xiyanping Injection (喜炎平注射液)] plus WM therapy (227 cases, CM plus WM therapy group) for 7–10 days, according to a web-based randomization system. The primary outcome was fever clearance time, which was presented as temperature decreased half-life time. The secondary outcomes included the rate of rash/herpes disappearance within 120 h, as well as the rate for cough, runny nose, lethargy and weakness, agitation or irritability, and vomiting clearance within 120 h. The drug-related adverse events were also recorded.
Results
The temperature decreased half-life time was 40.4 h in the WM therapy group, significantly longer than 27.2 h in the CM plus WM therapy group (P<0.01). Moreover, the rate for rash/herpes disappearance within 120 h was 43.6% (99/227) in the CM plus WM therapy group, significantly higher than 29.5% (66/224) in the WM therapy group (P<0.01). In addition, the rate for cough, lethargy and weakness, agitation or irritability disappearance within 120 h was 32.6% (74/227) in the CM plus WM therapy group, significantly higher than 19.2% (43/224) in the WM therapy group (P<0.01). No drug-related adverse events were observed during the course of the study.
Conclusion
The combined CM and WM therapy achieved a better therapeutic efficacy in treating severe HFMD than the WM therapy alone. Reduning or Xiyanping Injections may become an important complementary therapy to WM for relieving the symptoms of severe HFMD. (Registration No. NCT01145664)
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fan X, Jiang J, Liu Y, Huang X, Wang P, Liu L, et al. Detection of human enterovirus 71 and coxsackievirus A16 in an outbreak of hand, foot, and mouth disease in Henan Province, China in 2009. Virus Genes 2013;46:1–9.
Wu Y, Yeo A, Phoon MC, Tan EL, Poh CL, Quak SH, et al. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis 2010;14:e1076-e101081.
Zhu J, Luo Z, Wang J, Xu Z, Chen H, Fan D, et al. Phylogenetic analysis of enterovirus 71 circulating in Beijing, China from 2007 to 2009. PloS One 2013;8:e56318.
Zhang J, Sun J, Chang Z, Zhang W, Wang Z, Feng Z. Characterization of hand, foot, and mouth disease in China between 2008 and 2009. Biomed Environ Sci 2011;24:214–221.
Zhou H, Guo S, Zhou H, Zhu Y, Zhang L, Zhang W. Clinical characteristics of hand, foot and mouth disease in Harbin and the prediction of severe cases. Chin Med J 2012;125:1261–1265.
Zhu Q, Hao Y, Ma J, Yu S, Wang Y. Surveillance of hand, foot, and mouth disease in mainland China (2008–2009). Biomed Environ Sci 2011;24:349–356.
National Health and Family Planning Commission of the People's Republic of China. Report of epidemic situation of infectious disease in China from January of 2010 to January of 2011. Available at http://www.moh.gov.cn/publicfiles/ business/htmlfiles/mohjbyfkzj/s3578/201102/50646.htm.
Tian H, Yang QZ, Liang J, Dong SY, Liu ZJ, Wang LX. Clinical features and management outcomes of severe hand, foot and mouth disease. Med Princ Pract 2012;21:355–359.
National Health and Family Planning Commission of the People's Republic of China. Guideline for the diagnosis and treatment of hand foot and mouth disease, Beijing, China, 2010. Available at http://www.nhfpc.gov.cn/mohyzs/ s3586/201004/46884.shtml
Xue B, Yao Z, Yu R. Studies on anti-EV71 virus activity of traditional Chinese medicine and its clinical application in treatment of HFMD. China J Chin Mater Med (Chin) 2011;36:3366–3370.
Lin TY, Liu YC, Jheng JR, Tsai HP, Jan JT, Wong WR, et al. Anti-enterovirus 71 activity screening of Chinese herbs with anti-infection and inflammation activities. Am J Chin Med 2009;37:143–158.
Mu Y, Chen X, Zhang A. Effect of Reduning Injection on HFMD in children: a randomized controlled trial. Chin J Integr Tradit West Med (Chin) 2011;31:1209–1212.
Li X, Zhang C, Shi Q, Yang T, Zhu Q, Tian Y, et al. Improving the efficacy of conventional therapy by adding andrographolide sulfonate in the treatment of severe hand, foot, and mouth disease: a randomized controlled trial. Evid Based Complement Alternat Med 2013;2013:316250.
Cao H, Liu Z, Steinmann P, Mu Y, Luo H, Liu J. Chinese herbal medicines for treatment of hand, foot and mouth disease: a systematic review of randomized clinical trials. Eur J Integr Med 2012;4:e85-e111.
Pharmacopoeia Committee of People's Republic of China. Chinese pharmacopoeia. Beijing: Chemical Industry Press;2005.
Wang C, Cao B, Liu QQ, Zou ZQ, Liang ZA, Gu L, et al. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann Intern Med 2011;155:217–225.
Zu M, Zhou D, Gao L, Liu A, Du G. Evaluation of Chinese traditional patent medicines against influenza virus in vitro. Acta Pharmaceut Sinica (Chin) 2010;45:408–412.
Lu C, Liu X, Ding X, Chen X, Fan H, Liu Y, et al. A metabolomics profiling study in hand-foot-and-mouth disease and modulated pathways of clinical intervention using liquid chromatography/quadrupole time-of-flight mass spectrometry. Evid Based Complement Alternat Med 2013;2013:647452.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Li, Xh., Li, Sj., Xu, Y. et al. Effect of integrated Chinese and Western medicine therapy on severe hand, foot and mouth disease: A prospective, randomized, controlled trial. Chin. J. Integr. Med. 23, 887–892 (2017). https://doi.org/10.1007/s11655-016-2504-3
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11655-016-2504-3